Genomic predictors and oncogenic drivers in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers, and is a major health problem. Its incidence is growing and with more than 700,000 annual cases worldwide -50,000 in Europe-, it is the 3rd cause of cancer-related mortality. Most patients are diagnosed at advanced stages with dismal survival rates lower than 1 year, even after sorafenib, the sole systemic therapy available. The main goal of the HEPTROMIC project is to produce breakthrough knowledge in two critical aspects of HCC research: prognostic prediction and identification of oncogenic drivers susceptible for intervention, leading towards more personalized treatment algorithms. The HEPTROMIC Consortium proposes a 3-year translational research study bringing together an outstanding team of researchers with clinical and genomic expertise along with cutting-edge technology. Eight partners -six academic and two SMEs- will address the following objectives by applying high-end transcriptome, methylome and deep sequencing technology in a large set of 1,140 human samples: Objective 1) Genomic characterization of poor prognosis subclass of hepatocellular carcinoma. Objective 2) Identification of driver oncogenic events as potential treatment targets. Findings obtained will be confirmed in sophisticated experimental models that closely mimics human liver cancer. Objective 3) Design of prognostic devices for clinical translation. This transfer of knowledge will be led by SMEs with entrepreneurial management skills with experience in creating new products increasing European competitiveness and boosting the innovative capacity of industries. Overall, the Consortium foresees impacts on improved patient survival by refining prognosis and decision-making, identifying targets amenable for selective therapies and by improving the allocation of resources. In summary, HEPTROMIC will strength links between the academic and industry spheres, ultimately contributing to reduce liver cancer mortality. 


Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Barcelona, Catalonia, Spain

Institut National de la Santé et de la Recherche Médicale (INSERM). Paris, France

Fundació Privada Institut d'Investigació Biomèdica de Bellvitge (IDIBELL). Barcelona, Catalonia, Spain

Helmholtz Zentrum Für Infektionsforschung (HZI). Braunschweig, Germany

Fondazione IRCCS Istituto Nazionale dei tumori (INT). Milan, Italy

Broad Institute, Harvard. Boston, USA

Diagenode. Liège, Belgium

TcLand Expression SA. Nantes, France


Beteiligte Gruppen

Es gibt keine Ergebnisse


Lars Zender


Consorci Institut D’Investigacions



Geldgeber / Förderer

EU - Europäische Union